annb0t
Top 20
ResMed (NYSE:RMD) Third Quarter 2024 Results
Key Financial Results
Revenue: US$1.20b (up 7.2% from 3Q 2023). Net income: US$300.5m (up 29% from 3Q 2023). Profit margin: 25% (up from 21% in 3Q 2023). The increase in margin was driven by higher revenue. EPS: US$2.05 (up from US$1.58 in 3Q 2023). earnings-and-revenue-history
All figures shown in the chart above are for the trailing 12 month (TTM) period
ResMed Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 2.1%. ...
>>> Read more: ResMed Third Quarter 2024 Earnings: Beats Expectations
Key Financial Results
Revenue: US$1.20b (up 7.2% from 3Q 2023). Net income: US$300.5m (up 29% from 3Q 2023). Profit margin: 25% (up from 21% in 3Q 2023). The increase in margin was driven by higher revenue. EPS: US$2.05 (up from US$1.58 in 3Q 2023). earnings-and-revenue-history
All figures shown in the chart above are for the trailing 12 month (TTM) period
ResMed Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 2.1%. ...
>>> Read more: ResMed Third Quarter 2024 Earnings: Beats Expectations
